All In Biotech

Drug Trial Radar · NCT00294515

IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients

Last checked: Nov 20, 2026Latest source record: Mar 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

326

Actual

Start

Mar 31, 2006

Primary completion

Aug 31, 2008

Study completion Aug 31, 2009

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 22, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will determine the relative efficacy and safety of up to 100 days Valcyte prophylaxis relative to up to 200 days Valcyte prophylaxis when given for the prevention of CMV disease in high-risk (D+/R-) kidney allograft recipients. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

Conditions

  • Cytomegalovirus Infections

Interventions

  • ValganciclovirDrug

    900 mg orally daily for up to 100 days

  • ValganciclovirDrug

    900 mg orally daily for up to 200 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplantTime frame: 12 months post-transplant

Locations

80 sites in 13 countries. Site status is shown where the registry gives one.

  • Uni of Alabama At Birmingham

    Birmingham, Alabama

  • National Institute of Transplantation

    Los Angeles, California

  • UCLA Medical Center

    Los Angeles, California

  • Ucsd Medical Center; Kidney Transplantation

    San Diego, California

  • California Pacific Medical Center

    San Francisco, California

  • Uni of California San Francisco; Transplant Services

    San Francisco, California

  • Lifelink Healthcare Inst.

    Tampa, Florida

  • Rush-Presbyterian St. Luke'S Medical Center; Rush Uni Renal Transplant Program

    Chicago, Illinois

  • Indiana Uni Medical Center; Surgery & Microbiology/Immunology

    Indianapolis, Indiana

  • New England Medical Center; Division of Transplant Surgery

    Boston, Massachusetts

  • Uni of Michigan Medical Center

    Ann Arbor, Michigan

  • Uni of Minnesota Medical Center; Dept of Surgery

    Minneapolis, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • St. Barnabas Medical Center

    Livingston, New Jersey

  • Robert Wood Johnson Uni Hospital; Anesthesia

    New Brunswick, New Jersey

  • Wake Forest Uni School of Medicine; Section on Infectious Diseases

    Winston-Salem, North Carolina

  • Oregon Health Sciences Uni ; Division of Nephrology

    Portland, Oregon

  • Hahnemann Uni Hospital; Division of Transplant/Dept. of Surgery

    Philadelphia, Pennsylvania

  • Uni of Pennslyvania Medical Center

    Philadelphia, Pennsylvania

  • Vanderbilt Uni ; Divison of Nephrology

    Nashville, Tennessee

  • Texas Transplant Inst.

    San Antonio, Texas

  • Uni of Texas Health Science Center At San Antonio; Organ Transplant Program

    San Antonio, Texas

  • Uni of Washington Medical Center; Division of Allergy & Infectious Diseases

    Seattle, Washington

  • Royal Prince Alfred Hospital; Renal Transplant Unit

    Camperdown, New South Wales, Australia

  • Monash Medical Centre; Renal Transplant Unit

    Clayton, Victoria, Australia

  • Royal Melbourne Hospital; Nephrology

    Parkville, Victoria, Australia

  • Clin Univ de Bxl Hôpital Erasme

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital das Clinicas - UNICAMP

    Campinas, São Paulo, Brazil

  • Hospital Israelita Albert Einstein; Intensive Care Unit

    São Paulo, São Paulo, Brazil

  • Faculdade de Medicina de Ribeirao Preto Usp; Campus Uni Rio

    São Paulo, São Paulo, Brazil

  • Uni of Alberta Hospital

    Edmonton, Alberta, Canada

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Mcgill University - Royal Victoria Hospital; Oncology

    Montreal, Quebec, Canada

  • Hopital Pellegrin; Departement Nephrologie

    Bordeaux, France

  • Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie

    Grenoble, France

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.